S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression

Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen:
https://osnadocs.ub.uni-osnabrueck.de/handle/urn:nbn:de:gbv:700-2016111415145
Open Access logo originally created by the Public Library of Science (PLoS)
Langanzeige der Metadaten
DC ElementWertSprache
dc.creatorAmbrée, Oliver
dc.creatorBergink, Veerle
dc.creatorGrosse, Laura
dc.creatorAlferink, Judith
dc.creatorDrexhage, Hemmo A
dc.creatorRothermundt, Matthias
dc.creatorArolt, Volker
dc.creatorBirkenhäger, Tom K
dc.date.accessioned2016-11-14T07:24:08Z
dc.date.available2016-11-14T07:24:08Z
dc.date.issued2016-11-14T07:24:08Z
dc.identifier.citationInternational Journal of Neuropsychopharmacology, 19(3), 2015:pyv103.
dc.identifier.urihttps://osnadocs.ub.uni-osnabrueck.de/handle/urn:nbn:de:gbv:700-2016111415145-
dc.description.abstractBackground: There is an ongoing search for biomarkers in psychiatry, for example, as diagnostic tools or predictors of treatment response. The neurotrophic factor S100 calcium binding protein B (S100B) has been discussed as a possible predictor of antidepressant response in patients with major depression, but also as a possible biomarker of an acute depressive state. The aim of the present study was to study the association of serum S100B levels with antidepressant treatment response and depression severity in melancholically depressed inpatients. Methods: After a wash-out period of 1 week, 40 inpatients with melancholic depression were treated with either venlafaxine or imipramine. S100B levels and Hamilton Depression Rating Scale (HAM-D) scores were assessed at baseline, after 7 weeks of treatment, and after 6 months. Results: Patients with high S100B levels at baseline showed a markedly better treatment response defined as relative reduction in HAM-D scores than those with low baseline S100B levels after 7 weeks (P=.002) and 6 months (P=.003). In linear regression models, S100B was a significant predictor for treatment response at both time points. It is of interest to note that nonresponders were detected with a predictive value of 85% and a false negative rate of 7.5%. S100B levels were not associated with depression severity and did not change with clinical improvement. Conclusions: Low S100B levels predict nonresponse to venlafaxine and imipramine with high precision. Future studies have to show which treatments are effective in patients with low levels of S100B so that this biomarker will help to reduce patients’ burden of nonresponding to frequently used antidepressants.eng
dc.relationhttp://ijnp.oxfordjournals.org/content/19/3/pyv103.long
dc.rightsNamensnennung 3.0 Unported-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/-
dc.subjectmajor depressioneng
dc.subjectpredictive biomarkereng
dc.subjectantidepressant responseeng
dc.subjecttreatment resistanceeng
dc.subjectneurotrophic factoreng
dc.subject.ddc610 - Medizin und Gesundheit
dc.subject.ddc570 - Biowissenschaften; Biologie
dc.titleS100B Serum Levels Predict Treatment Response in Patients with Melancholic Depressioneng
dc.typeEinzelbeitrag in einer wissenschaftlichen Zeitschrift [article]
dc.subject.bk44.91 - Psychiatrie, Psychopathologie
dc.identifier.doi10.1093/ijnp/pyv103
vCard.ORGFB5
Enthalten in den Sammlungen:FB05 - Hochschulschriften

Dateien zu dieser Ressource:
Datei Beschreibung GrößeFormat 
pyv103SupplementaryMaterial_correctedOA.docxSupplementary data313,44 kBMicrosoft Word XML
pyv103SupplementaryMaterial_correctedOA.docx
Öffnen/Anzeigen
pyv103.full.pdfArticle849,55 kBAdobe PDF
pyv103.full.pdf
Miniaturbild
Öffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons